2234: Obesity, Adipokines, and Chronic and Persistent Pain in Rheumatoid Arthritis

Joshua Baker¹, Kristin Wipfler², Marianna Olave³, Sofia Pedro⁴, Patricia Katz⁵ and Kaleb Michaud⁶, ¹University of Pennsylvania, Philadelphia, PA, ²FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ³Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, ⁴Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ⁵UCSF, San Rafael, CA, ⁶University of Nebraska Medical Center, Omaha, NE

Background/Purpose: Obesity has been linked to chronic pain and pain sensitization in the general population and among patients with rheumatoid arthritis (RA). The mechanism by which obesity leads to pain sensitization remains unclear. Adipocytokines, including adiponectin, leptin, and Fibroblast Growth Factor-21, are metabolic regulators that are highly associated with obesity and inflammation and may serve many biologic functions surrounding energy utilization. Associations between adipokines and chronic pain has been observed in other settings. We aimed to determine whether adipocytokines are associated with pain, polysymptomatic distress, and trajectories of pain in patients with RA over time in a large patient registry.

Methods: The study was conducted in a subset of Forward; a patient-based multi-disease, multi-purpose rheumatic disease registry with patients enrolled from community-based rheumatology practices across the United States.. Adipocytokines were measured on stored serum. Body mass index (BMI), pain on visual analogue scale (VAS), polysymptomatic distress, and other patient-reported outcomes (PROs) were reported on bi-annual questionnaires. Linear regression was used to evaluate independent associations between obesity, adipocytokines, and PROs at the time of laboratory assessment. Cox proportional hazards models were used to evaluate independent associations between adipocytokines (leptin, adiponectin, fibroblast growth factor [FGF]-21) and clinically meaningful changes in pain over time – defined as a change of more than 1.1 in visual analogue scale (VAS) sustained over two surveys. These models were adjusted for demographics, baseline pain, BMI, C-Reactive Protein levels, anti-citrullinated protein autoantibodies (ACPA) status, the rheumatic disease comorbidity index (RDCI), osteoarthritis, depression, and diabetes.

Results: Among 645 patients included in these analyses, there were significant differences in RA characteristics, comorbidity, PROs, and adipokines across obesity categories (Table 1). Of note, severely obese patients were more likely to experience greater pain on VAS and greater polysymptomatic distress. Higher FGF-21 levels were independently associated with greater pain and greater polysymptomatic distress at baseline and over subsequent observations (Table 1), as well as a higher probability of taking opioids [OR per 1 SD: 1.50 (1.21, 1.85) p< 0.001] at baseline. Higher FGF-21 levels were also associated with higher likelihood of worsening pain over time (Figure 1), and a nonsignificant decrease in the likelihood of improving [HR (per 1 SD): 0.87 (0.73, 1.03) p=0.10].

Conclusion: Severe obesity and elevated levels of FGF-21 are each independently associated with pain, polysymptomatic distress, and opioid use in RA. Elevated FGF-21 levels may help identify those at risk of worsening pain trajectories. Mechanistic studies are needed to determine if adipocytokines could serve as targets for interventions.
Table 1: Associations between BMI and adipokines with pain by visual analogue scale (VAS) and the polysymptomatic distress (PSD) scale at the laboratory observation and over all subsequent observations. All models included each adipokine and BMI category, and were adjusted for age, sex, white race, RDCI, osteoarthritis, depression, diabetes, CRP, and ACPA serostatus.
*p=0.05; **p < 0.01; ***p < 0.001

Figure 1: Association between adiponectin (per 1 SD) (black square), FGF-21 (per 1 SD) (white circle), and leptin (per 1 SD) (gray diamonds) with clinically significant worsening in pain.
Disclosures: J. Baker, Bristol-Myers Squibb(BMS), RediTrex, Pfizer; K. Wipfler, None; M. Olave, None; S. Pedro, None; P. Katz, None; K. Michaud, None.